55 Grosvenor Street
26 articles with Atlas Venture
Atlas Venture, a leading early stage venture capital firm, announced that Samantha Truex is joining the firm as a venture partner.
Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, announced that Rajesh Devraj, PhD, is joining the firm as a venture partner.
Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, announced the closing of its twelfth fund, raising $400 million in a highly oversubscribed fundraise.
With the close of the fund, Atlas Venture said it will continue to advance its mission of “doing well by doing good” and building biotech companies that will deliver high-impact therapies to patients.
Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
Quench Bio, a company leveraging new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, announced the completion of a $50 million Series A financing led by RA Capital Management, with participation from new Investor Abbvie Ventures.
Atlas Venture announced the launch of Korro Bio, Inc., a new company created to lead the rapidly advancing field of RNA editing.
In Wake of Terminations, Pharma Leaders Decry Actions That Will Limit Collaborations with Foreign...
8/23/2019Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States.
Atlas Venture, F-Prime Capital, RA Capital Management, and Osage University Partners to Host Second Annual Science2Startup Symposium
Science2Startup Symposium Will Take Place in Cambridge on April 23, 2019, at the Broad Institute of MIT and Harvard
In a reflection on the annual healthcare conference, VC Bruce Booth criticizes the high cost of attending JPM, as well as the focus on market share instead of patients.
New fund will invest growth capital in Atlas-backed biotech companies
Generation Bio today announced the appointment of Jeff Jonas, M.D., chief executive officer of Sage Therapeutics, to its Board of Directors.
Andrea will lead the talent acquisition efforts for Atlas and work closely with companies incubating at Atlas and across the emerging portfolio on recruiting and organizational development.
Nessan will be involved with the formation and leadership of groundbreaking new biotechnology companies as part of the Atlas platform.
Generation Bio is developing a breakthrough class of genetic medicines based on its proprietary GeneWave technology
The company's demise was explained in a blog post by Atlas Venture partner Bruce Booth.
Cambridge Upstart IFM Therapeutics Banks $27 Million from Investors Like Novartis AG and Atlas Venture